Valuation: AAP IMPLANTATE

Market Cap 23.51M 26.42M 21.95M 20.02M 37.56M 2.55B 38.11M 265M 103M 1.3B 99.19M 97.05M 4.18B P/E 2024
-3.6x
P/E 2025 -7.58x
Enterprise Value 23.19M 26.07M 21.66M 19.75M 37.06M 2.51B 37.6M 262M 101M 1.28B 97.86M 95.75M 4.12B EV / Sales 2024
1.32x
EV / Sales 2025 1.56x
Free-Float
38.19%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 64 30/04/2019
Director of Finance/CFO - 18/08/2026
Chief Operating Officer - 18/08/2026
Director TitleAgeSince
Director/Board Member 70 31/12/2015
Chairman 55 03/07/2019
Director/Board Member 50 31/10/2021
Change 5-day change 1-year change 3-year change Capi.($)
-2.17%-6.57%-27.81%-0.17% 171B
+0.17%-3.20%-9.24%+10.31% 110B
-0.88%-0.16%-26.16%-0.11% 106B
-0.69%-3.57%-47.61%-12.45% 75.99B
+3.17%-0.80%-0.88%+72.13% 57.3B
-0.52%-2.44%-4.86%-31.12% 48.76B
+3.44%+7.90%+19.12%+59.15% 50.19B
-0.85%-0.82%-18.96%+18.41% 41.14B
-0.07%-1.71%+28.15%-7.58% 32.56B
Average +0.12%-1.46%-9.81%+12.06% 77B
Weighted average by Cap. -0.38%-2.07%-16.38%+9.01%

Financials

2024 2025
Net sales 12.2M 13.71M 11.39M 10.39M 19.5M 1.32B 19.78M 138M 53.34M 673M 51.49M 50.38M 2.17B 12.49M 14.03M 11.66M 10.63M 19.95M 1.35B 20.25M 141M 54.58M 689M 52.69M 51.55M 2.22B
Net income -3.63M -4.08M -3.39M -3.09M -5.8M -393M -5.89M -40.99M -15.87M -200M -15.32M -14.99M -645M -2.58M -2.91M -2.41M -2.2M -4.13M -280M -4.19M -29.19M -11.3M -143M -10.91M -10.67M -459M
Net Debt -1.1M -1.24M -1.03M -938K -1.76M -119M -1.79M -12.43M -4.81M -60.76M -4.65M -4.55M -196M -314K -353K -293K -267K -502K -34M -509K -3.55M -1.37M -17.33M -1.32M -1.3M -55.77M
Logo AAP IMPLANTATE
aap Implantate AG is a Germany-based provider of medical devices for human muscular and skeletal systems. The Company focuses on trauma and biomaterials products for orthopedics. The Biomaterials portfolio comprises bone substitutes for the filling of aseptic bone defects, bone cements and accessories for the application in arthroplasty, bone cements and accessories for the application in vertebroplasty and kyphoplasty. The trauma portfolio includes a wide range of cannulated screws, standard plates and screws for miniature, small and large bone fragments, among others . It also develops LOQTEQ, a technology that allows for fracture compression with subsequent locking fixation in one surgical step. The Company operates a network of distributors in more than 60 countries, and cooperates directly with physicians and hospital customers.
Employees
-